Koers Cyxone AB (publ) Nasdaq Stockholm
Aandelen
SE0007815428
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 30,77 mln. 2,87 mln. 2,64 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -28 mln. -2,61 mln. -2,4 mln. | Nettowinst (verlies) 2025 * | -38 mln. -3,55 mln. -3,26 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 1 mln. 93,34K 85,84K | Nettoliquiditeiten 2025 * | 41 mln. 3,83 mln. 3,52 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,1
x | K/w-verhouding 2025 * |
-0,79
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,97% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 20-05-21 | |
Founder | 58 | 01-01-15 | |
Malin Lindskog
DFI | Director of Finance/CFO | 63 | 15-06-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 58 | 01-01-15 | |
Director/Board Member | 58 | 01-01-15 | |
Michael Oredsson
CHM | Chairman | 64 | 01-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+10,23% | 9,11 mld. | |
-10,76% | 5,21 mld. | |
+51,58% | 4,83 mld. | |
+12,50% | 4,09 mld. | |
-20,70% | 2,35 mld. | |
+12,83% | 2,32 mld. | |
+19,51% | 2,27 mld. | |
-29,65% | 2,19 mld. | |
-0,50% | 1,64 mld. |